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Abstract
Background: Severe malaria is a leading cause of childhood mortality in Africa. However, at presentation, it is difficult to
predict which children with severe malaria are at greatest risk of death. Dysregulated host inflammatory responses and
endothelial activation play central roles in severe malaria pathogenesis. We hypothesized that biomarkers of these
processes would accurately predict outcome among children with severe malaria.
Methodology/Findings: Plasma was obtained from children with uncomplicated malaria (n=53), cerebral malaria (n=44)
and severe malarial anemia (n=59) at time of presentation to hospital in Kampala, Uganda. Levels of angiopoietin-2, von
Willebrand Factor (vWF), vWF propeptide, soluble P-selectin, soluble intercellular adhesion molecule-1 (ICAM-1), soluble
endoglin, soluble FMS-like tyrosine kinase-1 (Flt-1), soluble Tie-2, C-reactive protein, procalcitonin, 10 kDa interferon
gamma-induced protein (IP-10), and soluble triggering receptor expressed on myeloid cells-1 (TREM-1) were determined by
ELISA. Receiver operating characteristic (ROC) curve analysis was used to assess predictive accuracy of individual biomarkers.
Six biomarkers (angiopoietin-2, soluble ICAM-1, soluble Flt-1, procalcitonin, IP-10, soluble TREM-1) discriminated well
between children who survived severe malaria infection and those who subsequently died (area under ROC curve.0.7).
Combinational approaches were applied in an attempt to improve accuracy. A biomarker score was developed based on
dichotomization and summation of the six biomarkers, resulting in 95.7% (95% CI: 78.1–99.9) sensitivity and 88.8% (79.7–
94.7) specificity for predicting death. Similar predictive accuracy was achieved with models comprised of 3 biomarkers.
Classification tree analysis generated a 3-marker model with 100% sensitivity and 92.5% specificity (cross-validated
misclassification rate: 15.4%, standard error 4.9%).
Conclusions: We identified novel host biomarkers of pediatric severe and fatal malaria (soluble TREM-1 and soluble Flt-1)
and generated simple biomarker combinations that accurately predicted death in an African pediatric population. While
requiring validation in further studies, these results suggest the utility of combinatorial biomarker strategies as prognostic
tests for severe malaria.
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Introduction
Plasmodium falciparum malaria causes almost one million deaths
annually, mostly among young children in sub-Saharan Africa [1].
The most common manifestations of pediatric severe malaria are
severe malarial anemia (SMA) and cerebral malaria (CM). These
syndromes can have case fatality rates as high as 20% [2]. It is
challenging at clinical presentation to accurately determine which
children with severe malaria are at greatest risk of death. Simple
and sensitive clinical scores have been developed to predict
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17440outcome, but they have low specificity and rely on subjective
assessment of clinical signs [3,4]. An accurate prognostic test
would be useful for targeting limited health resources to high-risk
children and for selecting patients to enroll in clinical trials of
adjunctive therapies for severe malaria.
Investigations into malaria pathogenesis have implicated host
pathways in disease progression. In particular, dysregulated
inflammatory responses and endothelial activation are thought
to be central processes in severe malaria pathogenesis [5–7]. We
hypothesized that plasma biomarkers of these pathways may have
clinical utility as prognostic tools, particularly if used in
combination. We examined biomarkers of these pathways for
their utility as indicators of disease severity and outcome in
Ugandan children presenting to hospital with malaria.
Excessive pro-inflammatory responses to infection are observed
in both CM and SMA [8–11]. In this study, we measured plasma
levels of acute-phase response components, C-reactive protein
(CRP) and procalcitonin (PCT), which have been shown to
increase during malaria infection [12,13]. We also measured
10 kDa interferon gamma-induced protein (IP-10), a chemokine
reported to be elevated in fatal CM [14]. Moreover, we assessed
levels of soluble triggering receptor expressed on myeloid cells-1
(sTREM-1), which is associated with inflammatory conditions [15]
but has not been previously investigated in malaria.
Dysregulated inflammation is thought to promote CM in part
through endothelial activation in the brain. Pro-inflammatory
cytokines upregulate cell adhesion receptors (e.g., intercellular
adhesion molecule-1 [ICAM-1]) that mediate sequestration of
parasitized erythrocytes in brain microvasculature, leading to vessel
occlusion [16] and blood-brain barrier dysfunction [17]. Upon
endothelial activation, soluble endothelial cell receptors are released
via ectodomain shedding or alternative splicing. We measured the
soluble forms of ICAM-1 (sICAM-1) and the TGF-b receptor
endoglin (s-endoglin), which have both been shown to be increased
in severe malaria [18,19], and soluble FMS-like tyrosine kinase-1
(sFlt-1), which has been implicated in placental malaria [20].
Endothelial activation also causes exocytosis of Weibel-Palade
bodies (WPB), intracellular vesicles that contain a variety of effector
molecules [21]. We assayed WBP-associated factors angiopoietin-2
(Ang-2), von Willebrand factor (vWF), vWF propeptide, and soluble
P-selectin (sP-selectin). Some of these molecules are elevated in CM
[22–24] and have been suggested to contribute to pathology: Ang-2
may exacerbate vascular activation in malaria by antagonizing the
quiescence-promoting interaction of the endothelial Tie-2 receptor
with angiopoietin-1 (Ang-1) [25], while vWF may help tether
parasitized erythrocytes to endothelial cells via platelets [26]. In
addition to CM patients, systemic endothelial activation has been
shown to occur in adults with uncomplicated and non-CM severe
malaria [19,27]; however, few studies have characterized the extent
and significance of this process in pediatric SMA.
In this study, we examined plasma biomarkers of inflammation and
endothelial activation in children presenting to hospital with malaria.
We determined which markers were elevated in severe disease
compared to uncomplicated malaria (UM), and which markers
discriminated between children who survived severe malaria infection
and those who subsequently died. Furthermore, we identified
combinations of biomarkers from these two host pathways that
accurately predicted mortality among children with severe malaria.
Methods
Ethics statement
Ethical approval for the study was obtained from the Mulago
Hospital Research Ethics Committee, Makerere University
Faculty of Medicine Research Ethics Committee, Uganda
National Council for Science & Technology, and the University
Health Network. Written informed consent was obtained from
parents/guardians before enrollment.
Study site and participants
This retrospective case-control study was nested within a larger
study conducted at Mulago Hospital in Kampala, Uganda
between October 2007 and October 2009. Mulago Hospital is a
national referral hospital that serves Kampala and surrounding
districts. Malaria transmission in this region and the patient
population at Mulago Hospital have been previously described
[28]. Children presenting to hospital were eligible for enrollment if
they were between 6 months and 12 years old and had
microscopy-confirmed P. falciparum infection (asexual parasitemia
with clinical signs or symptoms of malaria). Children were
excluded if they had sickle cell trait/disease, HIV co-infection,
or severe malnutrition. Clinical and demographic data were
collected upon enrollment, and venous blood samples were
collected for routine measurement of hemoglobin and platelet
count, and for plasma banking. Thin blood smears were obtained
at presentation for determination of parasitemia, which is reported
as the arithmetic mean of two independent readings by expert
microscopists. Treatment was in accordance with Ugandan
national guidelines: artemether/lumefantrine was administered
to children with uncomplicated malaria, and parenteral quinine
was used in severe malaria cases [29]. All children with SMA
received blood transfusions. Children were followed for recovery/
survival or death.
For biomarker analysis, a sub-group (n=156) of UM outpa-
tients, CM inpatients, and SMA inpatients in roughly equal
numbers was selected from the larger study based on availability of
an adequate volume of previously unthawed plasma. CM was
defined as an unrousable coma (not attributable to any other
cause) in a child with asexual P. falciparum parasitemia (i.e. Blantyre
Coma Scale score ,3, either before or .6 h after seizures or
anticonvulsant medication (if applicable), or repeated (.3) seizures
witnessed within a 24 h period, in the absence of hypoglycaemia
(,40 mg/dL or 2.2 mM) or any known alternative neurologic
abnormalities). SMA was defined as hematocrit,15% or hemo-
globin,5.0 g/dL in the presence of asexual parasitemia.
Biomarker assays
Plasma (sodium citrate anticoagulant) was stored at 220uC
prior to testing. ELISAs were used to quantify plasma biomarker
levels and were performed blinded to all associated clinical data.
The following markers were assayed (dilution factor indicated in
parentheses): Ang-2 (1:5), CRP (1:40,000), sTREM-1 (neat), s-
endoglin (1:25), IP-10 (1:2), sFlt-1 (1:6), sICAM-1 (1:1000), sP-
selectin (1:50), sTie-2 (1:25; all R&D Systems), PCT (1:5; Ray
BioTech), and vWF propeptide (1:400; Sanquin). ELISAs were
performed according to the manufacturers’ instructions, with the
following changes: assays were performed in a volume of 50 mL/
well; plasma samples were incubated overnight at 4uC; and
ELISAs were developed using ExtravidinH-Alkaline Phosphatase
(Sigma, 1:1000 dilution, 45 min incubation) followed by addition
of p-Nitrophenyl phosphate substrate (Sigma) and optical density
readings at 405 nm. s-endoglin and sP-selectin were only
measured in samples collected during the first year of the study
(n=101). For vWF, plates were coated with anti-human vWF
antibody (Dako, 1:600), incubated with samples (1:500 dilution)
and serial dilutions of recombinant vWF (American Diagnostica),
then incubated with horseradish peroxidase-conjugated anti-
human vWF (Dako, 1:8000). Assays were developed with
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Background signal was determined from blank wells included on
each plate (assay buffer added instead of sample), and background
optical density was subtracted from all samples and standards prior
to analysis. Samples with optical densities below the lowest
detectable standard were assigned the value of that standard.
Statistical analysis
GraphPad Prism v4, SPSS v18, and MedCalc software were
used for analysis. For clinical and demographic variables,
differences between groups were assessed using the Chi-square
test (categorical variables) or the Kruskal-Wallis test with Dunn’s
multiple comparison post-hoc tests (continuous variables). The
Mann-Whitney U test was used to compare biomarker levels
between groups, and p values were corrected for multiple
comparisons using Holm’s correction. Receiver operating char-
acteristic curves were generated using the non-parametric
method of Delong et. al [30]. Cut-points were determined using
the Youden index (J=max[sensitivity+specificity21]). For logistic
regression, linearity of an independent variable with the log odds
of the dependent was assessed by including a Box-Tidwell
transformation into the model and ensuring that this term was
not significant. Bootstrapping (1000 sample draws) was used to
generate variance estimates for b. Model goodness-of-fit was
assessed by the Hosmer-Lemeshow test and calibration slope
analysis [31]. Positive and negative predictive values were
calculated using the reported case fatality rate of 5.7% for
microscopy-confirmed CM and SMA at Mulago Hospital [28].
Classification tree analysis was performed in SPSS with the
following settings: minimum 10 cases for parent nodes and 5 for
child nodes; customized prior probabilities based on the case
fatality rate at Mulago Hospital; customized misclassification
costs (as indicated); pruning to reduce overfitting; and cross-
validation with 10 sample folds to generate an estimate of the
misclassification rate and its standard error. There were no
missing values from the dataset.
Results
Characteristics of study participants
Children presenting to Mulago Hospital in Kampala, Uganda
with UM (n=53), CM (n=44), and SMA (n=59) were included
in the study. Six children had concurrent CM and SMA and were
categorized as ‘‘CM’’, and five children with SMA exhibited
decreased consciousness but did not meet study criteria for CM.
Table 1 presents the demographic and clinical characteristics of
the three groups. Children with SMA were younger than children
with UM and CM (p,0.001) and presented significantly later than
the other groups (p,0.001, approximately one day later). Children
with severe malaria had lower hemoglobin levels and platelet
counts than children with UM.
Biomarker levels in uncomplicated vs. severe malaria
patients
Plasma samples obtained at presentation were assayed for
biomarkers of endothelial activation and inflammation (Fig. 1).
sICAM-1, sTie-2, and sFlt-1 weresignificantly increased in CM and
SMA compared to UM (p,0.01), while s-endoglin, sP-selectin, and
IP-10 did not differ between groups (p.0.05). WPB-associated
proteins Ang-2, vWF, and vWF propeptide were elevated in
children with severe malaria compared to UM, as were inflamma-
tory biomarkers CRP, PCT, and sTREM-1 (p,0.01).
Biomarkers as predictors of mortality in children with
severe malaria
To evaluate the prognostic utility of these plasma biomarkers,
we compared admission levels between children with severe
malaria who survived infection and those who subsequently died.
After correction for multiple comparisons, admission levels of Ang-
2 were significantly increased in CM fatalities compared to
survivors (Fig. 2A; p,0.05), while Ang-2, sICAM-1, IP-10
(p,0.01), sTREM-1 and sFlt-1 (p,0.05) were elevated in SMA
fatalities compared to survivors (Fig. 2B).
Table 1. Demographic and clinical characteristics of study participants presenting with uncomplicated and severe malaria.
a
Pooled severe malaria
Characteristic UM
b (n=53) CM
c (n=44) SMA (n=59) Survivors (n=80) Fatalities (n=23)
Gender (% female) 45.3 52.3 49.2 46.3 65.2
11
Age (years) 4.4 (2.1, 8.1) 3.0 (1.5, 4.3) 1.3 (0.9, 2.0)
***### 1.6 (1.0, 3.1) 1.9 (1.2, 3.3)
Days reported ill prior to
presentation
3 (2, 4) 3 (2, 4) 4 (3, 5)
***# 3 (3, 4) 3 (2, 7)
Parasitemia (parasites/uL) 3.8610
4
(1.6610
4,1 . 2 610
5)
9.8610
4
(1.5610
4,2 . 7 610
5)
2.6610
4
(7.4610
3,1 . 2 610
5)
#
3.7610
4
(7.5610
3, 1.5610
5)
1.6610
5
(2.2610
4,3 . 9 610
5)
1
Hemoglobin (g/dL) 10.1 (9.4, 11.3) 6.3 (5. 3, 8.4)
*** 3.8 (3.2, 4.4)
***### 4.3 (3.4, 5.6) 5.4 (4.2, 8.3)
1,d
Platelet count (610
9/L) 166 (107, 219) 73 (47, 128)
*** 116 (71, 165)
* 103 (61, 162) 73 (41, 128)
Fatal cases 0 14 9 0 23
aAll variables except gender are presented as median (interquartile range). Groups were compared using the Mann Whitney U test or Kruskal-Wallis test with Dunn’s
post-hoc tests (continuous variables) or Chi-square test (categorical variables).
bUM, uncomplicated malaria; CM, cerebral malaria; SMA, severe malaria anemia.
c6 children with concurrent CM and SMA were included in the CM group. 5 children with SMA exhibited decreased consciousness but did not meet criteria for CM.
dIncreased hemoglobin among fatalities was due to the higher CM:SMA ratio in this group vs survivors.
*p,0.05,
***p,0.001 CM or SMA vs. UM.
#p,0.05,
###p,0.001 SMA vs. CM.
1p,0.05,
11p,0.01 fatalities vs. survivors.
doi:10.1371/journal.pone.0017440.t001
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not the CM group aftercorrection for multiplecomparisons (sICAM-
1, IP-10, sTREM-1, sFlt-1) were significant or trending towards
significance in the CM group before the correction was applied. This
suggests that the apparent differences between syndromes may have
been due to low statistical power and therefore we combined all
severe malaria patients for further analysis. This strategy also avoids
the problem of classifying mixed clinical phenotypes, as occurred in
thepresentstudy population. Characteristics ofsurvivors and fatalities
were similar (Table 1), although among fatalities there was a greater
proportion of females (p=0.007) and increased parasitemia
(p=0.023). We found that Ang-2, sICAM-1, sFlt-1, IP-10, and
sTREM-1 (p,0.01), as well as PCT (p,0.05), were elevated in fatal
cases of severe malaria compared to survivors (Fig. 2C).
Figure 1. Plasma biomarker levels in Ugandan children with uncomplicated and severe malaria at time of presentation. Biomarkers of
inflammation and endothelial activation in the plasma of children with uncomplicated malaria (UM), cerebral malaria (CM), and severe malarial
anemia (SMA) were measured by ELISA. Data are presented as dot plots with medians. A Mann Whitney U test was performed for each comparison,
and p values were adjusted for multiple comparisons using Holm’s correction (n=24). ** p,0.01.
doi:10.1371/journal.pone.0017440.g001
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survivors and fatalities, we generated receiver operating charac-
teristic (ROC) curves and determined area under the curve (AUC)
(Fig. 3). Ang-2, sICAM-1, and IP-10 had excellent predictive
ability (AUC 0.8–0.9), and sTREM-1, sFlt-1 and PCT had
acceptable predictive ability (AUC 0.7–0.8) [32]. The AUC for
parasitemia, which is used in clinical practice as a prognostic factor
[33], was 0.66.
We used the Youden index to obtain a cut-point for each
biomarker, and evaluated clinical performance measures for these
dichotomized biomarkers (Table 2). sTREM-1 achieved the
highest sensitivity (95.7%) but had low specificity (43.8%), while
Figure 2. Plasma biomarker levels in children with severe malaria who survived or subsequently died from infection. Presented are
biomarkers that were significantly different for (A) CM patients only, (B) SMA patients only, and (C) all severe malaria patients combined. Biomarkers
were measured by ELISA. Data are presented as dot plots with medians. A Mann Whitney U test was performed for each comparison, and p values
were adjusted for multiple comparisons using Holm’s correction (n=12 for each group). * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0017440.g002
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sensitivity, 85% specificity).
Predicting mortality using a ‘‘biomarker score’’
We hypothesized that combining biomarkers would improve
predictive accuracy. The modest number of deaths in the study
precluded multivariable logistic regression analysis with more than
2–3 independent variables [34]. Therefore, as performed in other
conditions [35,36], we combined the biomarkers into a score. For
each marker, one point was assigned if the measured value was
greater than the corresponding cut-point, and zero points were
assigned if it was lower. A cumulative ‘‘biomarker score’’ was
calculated for each patient by summing the points for all six
markers. No two dichotomized biomarkers were highly correlated
(Spearman’s rho,0.6; data not shown), suggesting that each
biomarker would contribute unique information to the score.
Biomarker score was highly positively correlated with risk of death
(Fig. 4A; Spearman’s rho=0.96, p=0.003). Scores were elevated
Figure 3. Assessment of biomarker utility in predicting outcome in children with severe malaria. A receiver operating characteristic
(ROC) curve was generated for each biomarker. The dashed reference line represents the ROC curve for a test with no discriminatory ability. Area
under the ROC curve is displayed on each graph with 95% confidence intervals in parentheses. p values were adjusted for multiple comparisons using
Holm’s correction (n=7). * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0017440.g003
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range): 5 (4–6) and 1 (0–2.5), respectively). In a univariate logistic
regression model, the biomarker score was a significant predictor of
death with an odds ratio of 7.9 (95% CI 4.6–54.4) (Table 3, Model 1).
After adjustment for parasitemia and age, which have been associated
with malaria mortality, the score remained significant with an
adjusted odds ratio of 7.8 (4.7–134) (Table 3, Model 2).
ROC curve analysis and cut-point determination were per-
formed as above for the biomarker score. The AUC was 0.96
(0.90–0.99) (Fig. 4C), and we found that a score $4 was 95.7%
sensitive and 88.8% specific for predicting death in our sample
(Table 4, row 1). While the positive predictive value was low
(33.9%) given a fatality rate of 5.7%, the negative predictive value
(NPV) was 99.7%, indicating that a child with a score #3 will
likely respond well to standard treatment protocols.
A score involving fewer biomarkers might be expected to improve
practicality and facilitate potential translation to a clinical application.
Using the same scoring scheme, 2-marker combinations performed
poorly (data not shown). However, specific 3-marker combinations
yielded sensitivity.90% and specificity.80% (Table 4).
Predicting mortality using classification tree analysis
To explore another combinatorial strategy, we used classifica-
tion tree analysis, which selects and organizes independent
variables into a decision tree that optimally predicts the dependent
measure. Initially, a model based on IP-10 and sTREM-1 was
generated with 43.5% sensitivity and 100% specificity for
predicting mortality (data not shown). Since high sensitivity would
be a crucial feature of a prognostic test for severe malaria, we
repeated the analysis assigning the cost of misclassifying a death as
a survivor as 10 times greater than the cost of misclassifying a
survivor as a death. A model based on IP-10, Ang-2, and sICAM-1
was generated (Fig. 5), with 100% sensitivity and 92.5% specificity
for predicting outcome (cross-validated misclassification rate
15.4%, standard error 4.9%). In summary, combining dichoto-
mized biomarkers using a scoring system or a classification tree
predicted severe malaria mortality in our patient population with
high accuracy.
Discussion
Combinations of prognostic biomarkers, particularly if drawn
from distinct pathobiological pathways, have been found to
improve predictive accuracy [35]. In this study, we demonstrated
that simple schemes combining as few as 3 host biomarkers of
inflammation and endothelial activation predicted mortality with
high accuracy among a group of Ugandan children with severe
malaria. These findings provide support for the development of
prognostic tests for severe malaria based on host biomarker
combinations. Moreover, we further characterized WPB exocyto-
Table 2. Clinical performance of biomarkers for predicting mortality among children with severe malaria.
a
Biomarker Cut-point
b Sensitivity (%) Specificity (%) PLR
c NLR PPV (%)
d NPV (%)
Ang-2 .5.6 ng/mL 78.3 (56.3–92.5) 78.8 (68.2–87.1) 3.7 (2.9–4.7) 0.3 (0.1–0.7) 18.2 (5.8–38.7) 98.4 (92.4–99.9)
sICAM-1 .645.3 ng/mL 87.0 (66.4–97.2) 75.0 (64.1–84.0) 3.5 (2.8–4.3) 0.2 (0.06–0.5) 17.4 (5.9–35.9) 99.0 (93.2–100)
sFlt-1 .1066.3 pg/mL 82.6 (61.2–95.0) 57.5 (45.9–68.5) 1.9 (1.5–2.5) 0.3 (0.1–0.8) 10.5 (3.4–23.1) 98.2 (90.4–100)
PCT .43.1 ng/mL 56.5 (34.5–76.8) 82.5 (72.4–90.1) 3.2 (2.2–4.7) 0.5 (0.3–1.0) 16.3 (3.8–39.5) 96.9 (90.5–99.5)
IP-10 .831.2 pg/mL 82.6 (61.2–95.0) 85.0 (75.3–92.0) 5.5 (4.5–6.8) 0.2 (0.07–0.6) 25.0 (8.3–49.8) 98.8 (93.4–100)
sTREM-1 .289.9 pg/mL 95.7 (78.1–99.9) 43.8 (32.7–55.3) 1.7 (1.3–2.2) 0.1 (0.01–0.7) 9.3 (3.3–19.6) 99.4 (90.5–100)
aAll parameters are presented with 95% CIs in parentheses.
bCut-points were determined using the Youden Index (J=max[sensitivity+specificity21]).
cPLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.
dPPVs and NPVs were based on estimates that 5.7% of CM and SMA patients at Mulago hospital die of the malaria infection [28].
doi:10.1371/journal.pone.0017440.t002
Figure 4. The biomarker score is significantly associated with risk of fatality among children with severe malaria. The biomarker score
for each patient was calculated as detailed in the text. (A) Biomarker scores were plotted against observed probability of death. The two variables
were significantly related (Spearman’s rho=0.96, p=0.003). (B) Biomarker score distributions were plotted for severe malaria survivors and fatalities.
(C) A receiver operating characteristic (ROC) curve was generated for the biomarker score. The dashed reference line represents the ROC curve for a
test with no discriminatory ability. Area under the ROC curve is displayed on each graph with 95% confidence intervals in parentheses. *** p,0.001.
doi:10.1371/journal.pone.0017440.g004
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novel biomarkers of severe and fatal malaria in children, leading to
new hypotheses regarding severe malaria pathogenesis.
We found that plasma sTREM-1 levels reflected disease severity
in children with severe malaria. The TREM-1 receptor is
expressed on the cell membrane of monocytes and neutrophils
and mediates pro-inflammatory responses [37]. sTREM-1 is
generated by cleavage of membrane TREM-1 upon myeloid cell
activation [38]. Both membrane and soluble TREM-1 are
increased in inflammatory pathologies in humans [15], and
inhibition of TREM-1 improves outcome in murine models of
sepsis and inflammatory bowel disease [39,40]. Interestingly, a
recent report demonstrated increased levels of monocyte TREM-1
in uncomplicated malaria cases compared to uninfected individ-
uals [41]. Together, these findings raise the possibility that
TREM-1 may contribute to the excessive inflammation charac-
teristic of severe malaria.
sFlt-1 is generated by alternative splicing of VEGF receptor-1
mRNA and antagonizes the pro-inflammatory and pro-angiogenic
effects of VEGF. Our observation of increased sFlt-1 in severe
malaria parallels findings in sepsis patients [42]. Data from murine
models of sepsis suggest that sFlt-1 may have a protective role in
this disease, as sFlt-1 administration reduced VEGF-mediated
vascular permeability and mortality [43]. VEGF expression in the
brain was increased in European travellers who died of CM
compared to controls with non-neurological causes of death [44],
and plasma VEGF levels positively correlated with neurological
complications in African children with CM [45]. Thus, similarly to
sepsis, elevated sFlt-1 in severe malaria may represent a host
response to counter the pathological effects of excess VEGF.
However, the role of VEGF in malaria infection is controversial:
VEGF can also have neuroprotective effects, and some reports
have demonstrated decreasing plasma VEGF with increasing
malaria severity [24,46]. Further studies are required to delineate
the roles of sFlt-1/VEGF and sTREM-1 in severe malaria.
There were some discrepancies between our data and previous
studies of biomarkers in pediatric severe malaria. s-endoglin was
found to be increased in Gabonese children with severe malaria
compared to UM [18], but we did not replicate these results. We
observed similar levels of IP-10 in CM and SMA fatalities, in
contrast to a report that serum IP-10 was specifically elevated in
Ghanaian children who died from CM [14]. However, these
studies may not be comparable since blood was obtained post-
mortem in the Ghanaian study rather than at admission. It is also
possible that the above discrepancies are due to regional
differences in parasite strains, host genetics, and/or common co-
infections.
As previously described [22–24], we observed increased plasma
levels of WPB components Ang-2, vWF, and vWF propeptide in
CM vs. UM. We also demonstrated for the first time that these
factors are specifically elevated among children with SMA,
suggesting that extensive WPB exocytosis occurs not only in CM
but also in SMA. Few studies have directly addressed endothelial
activation in SMA [47]. WPB exocytosis can be induced by factors
generated during malaria infection (e.g., cytokines, histamine,
reactive oxygen species) that have been shown to be more elevated
in SMA compared to UM [9,48]. It is biologically plausible that
increased circulating levels of WPB contents could directly
contribute to the pathogenesis of SMA. Ang-2 sensitization of
endothelial cells to TNF [49] may amplify secretion of endothelial
cytokines, such as IL-6, that can promote anemia [50].
Interestingly, Ang-2 can impair maintenance of long-term
Table 3. Association of biomarker score with outcome among children with severe malaria: logistic regression.
a
Hosmer-Lemeshow test
Variable b (95% CI) SE Wald df p value OR (95% CI) Chi square df p value
Model 1
b Biomarker score 2.1 (1.5–4.0) 2.3 18.6 1 0.001 7.9 (4.6–54.4) 3.3 5 0.66
Model 2
c Biomarker score
d 2.1 (1.6–4.9) 21.5 18.2 1 0.001 7.8 (4.7–134) 1.1 8 1.0
Log parasitemia
e 0.050 ((21.1)–1.3) 2.8 0.010 1 0.91 1.1 (0.35–3.6)
Age 0.053 ((20.61)–1.2) 8.5 0.052 1 0.89 1.1 (0.55–3.3)
aThe reference category was ‘‘survival.’’
bPseudo-R
2 (Cox & Snell) 0.473 and calibration slope 0.98.
cPseudo-R
2 (Cox & Snell) 0.474 and calibration slope 1.0.
dBiomarker score and log parasitemia had a significant but low correlation (Spearman’s rho 0.292, p,0.01).
eParasitemia was log-transformed in order to achieve linearity with the log-odds of the dependent variable. SE, standard error; OR, odds ratio.
doi:10.1371/journal.pone.0017440.t003
Table 4. Clinical performance of biomarker combinations for predicting mortality among children with severe malaria.
a
Combination Cut-point
b Sensitivity (%) Specificity (%) PLR
c NLR PPV (%)
d NPV (%)
Biomarker score (6 markers) $4 95.7 (78.1–99.9) 88.8 (79.7–94.7) 8.5 (7.6–9.6) 0.05 (0.007–0.4) 33.9 (12.8–61.3) 99.7 (95.2–100)
Ang-2, PCT, sICAM-1 $2 91.3 (72.0–98.9) 88.8 (79.7–94.7) 8.1 (7.0–9.4) 0.1 (0.02–0.4) 32.9 (12.1–60.3) 99.4 (94.7–100)
Ang-2, IP-10, PCT $2 91.3 (72.0–98.9) 86.3 (76.7–92.9) 6.6 (5.7–7.7) 0.1 (0.02–0.4) 28.6 (10.2–54.4) 99.4 (94.6–100)
PCT, IP-10, sTREM-1 $2 91.3 (72.0–98.9) 81.3 (71.0–89.1) 4.9 (4.1–5.7) 0.1 (0.03–0.4) 22.7 (8.1–44.8) 99.4 (94.2–100)
aAll parameters are presented with 95% CIs in parentheses.
bCut-points were determined using the Youden Index (J=max[sensitivity+specificity21]).
cPLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value.
dPPVs and NPVs were based on estimates that 5.7% of CM and SMA patients at Mulago hospital die of the malaria infection [28].
doi:10.1371/journal.pone.0017440.t004
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the Tie-2/Ang-1 interaction [51]. While the role of LT-HSCs in
SMA requires clarification, it is interesting to speculate that
dysregulated Ang-2 levels may contribute to anemia via LT-HSC
depletion. Unfortunately we are unable to comment on the Ang-1
levels or Ang-2/Ang-1 ratios in these children due to poor
detectability of Ang-1 in citrated plasma.
Regardless of whether these biomarkers mediate or simply reflect
pathology, combinations of biomarkers accurately predicted mortal-
ity among children with severe malaria in our sample. Notably, some
biomarker combinations showed excellent sensitivity, ensuring that
the majority of children at high risk of death would be identified.
While an effective adjunctive therapy for severe malaria remains
elusive, prognostication could allow triage of patients for closer
monitoring or intensive care resources, as available. Such a test may
also assist in risk stratification and patient selection for clinical trials of
adjunctive therapies, which are ongoing [52,53].
Previous studies have developed clinical scores to prognosticate
outcome in pediatric severe malaria [3,4]. These scores incorpo-
rate clinical features such as prostration, coma, and respiratory
distress. The simplicity and low costs of these tests are attractive
features. However, a prognostic assay would ideally predict
mortality with both high sensitivity and specificity based on a
single criterion to avoid the uncertainty associated with non-
extreme scores. The biomarker combinatorial strategies presented
here appear to possess this attribute, although further studies are
required to confirm our findings. Another advantage of a
biomarker-based prognostic test over clinical assessment is its
objective quality that is unaffected by between-clinician variability.
Furthermore, advances in point-of-care platforms [54] may enable
development of affordable tests that integrate malaria diagnostics
with prognostic biomarkers.
The limitations to our study include a small sample size and the
use of non-consecutive samples, which may have introduced a
Figure 5. Classification tree analysis to predict outcome of severe malaria infection with host biomarkers. All six biomarkers that
discriminated survivors from fatalities were entered into the classification tree analysis. Prior probabilities of survival and death were specified (94.3%
and 5.7%, respectively). The cost of misclassifying a true death was designated as 10 times the cost of misclassifying a true survivor. The cut-points
selected by the analysis are indicated between parent and child nodes. Below each terminal node (i.e. no further branching), the predicted
categorization of all patients in that node is indicated. This model yielded 100% sensitivity and 92.5% specificity for predicting mortality (cross-
validated misclassification rate 15.4% with standard error 4.9%).
doi:10.1371/journal.pone.0017440.g005
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not assessed, and thus it is unclear how they may have affected
biomarker levels. Biomarker combinations that accurately pre-
dicted mortality require validation in larger prospective studies
with adjustment for potential demographic and clinical confound-
ers and head-to-head comparison with prognostic clinical scores.
Furthermore, these combinations require validation across differ-
ent ethnicities and malaria endemicities, as well as in children with
non-CM/non-SMA severe malaria syndromes. Nevertheless, this
study identified novel biomarkers in African children, who are at
the greatest risk of malaria mortality, and specifically in SMA, for
which few informative biomarkers have been described. We
provide proof-of-concept that combining as few as 3 biomarkers
using simple schemes may be able to accurately predict outcome in
severe malaria infection.
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